Long-term therapy of chronic delta hepatitis with peginterferon alfa

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 1, 2014, Pages 93-104

  Heller, T ^a   Rotman, Y ^a   Koh, C ^a   Clark, S ^a   Haynes Williams, V ^a   Chang, R ^b   McBurney, R ^b   Schmid, P ^c   Albrecht, J ^c   Kleiner, D E ^d   Ghany, M G ^a   Liang, T J ^a   Hoofnagle, J H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c National Genetics Institute   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON ALPHA2A;

ADULT; ANEMIA; ARTICLE; AUTOINFLAMMATORY DISEASE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CYTOPENIA; DELTA AGENT HEPATITIS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOOT ULCER; HEADACHE; HEPATIC VENOUS PRESSURE GRADIENT; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LONG TERM CARE; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; SEROCONVERSION; SOFT TISSUE INFECTION; SUBARACHNOID HEMORRHAGE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS D, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902078991     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12788     Document Type: Article

References (42)

1. Hughes SA, Wedemeyer H, Harrison PM,. Hepatitis delta virus. Lancet 2011; 378: 73-85.
2. Gudima S, Chang J, Moraleda G, Azvolinsky A, Taylor J,. Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA. J Virol 2002; 76: 3709-19.
3. Glenn JS, Marsters JC Jr, Greenberg HB,. Use of a prenylation inhibitor as a novel antiviral agent. J Virol 1998; 72: 9303-6.
4. Rizzetto M,. Hepatitis D: thirty years after. J Hepatol 2009; 50: 1043-50.
5. Rizzetto M, Ponzetto A, Forzani I,. Hepatitis delta virus as a global health problem. Vaccine 1990; 8 (Suppl.): S10-4.
6. Govindarajan S, Kanel GC, Peters RL,. Prevalence of delta-antibody among chronic hepatitis B virus infected patients in the Los Angeles area: its correlation with liver biopsy diagnosis. Gastroenterology 1983; 85: 160-2.
7. Colombo M, Cambieri R, Rumi MG, Ronchi G, Del Ninno E, De Franchis R,. Long-term delta superinfection in hepatitis B surface antigen carriers and its relationship to the course of chronic hepatitis. Gastroenterology 1983; 85: 235-9.
8. Manesis EK, Vourli G, Dalekos G, et al,. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol 2013; 59: 949-56.
9. Fattovich G, Giustina G, Christensen E, et al,. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46: 420-6.
10. Ji J, Sundquist K, Sundquist J,. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst 2012; 104: 790-2.
11. Romeo R, Del Ninno E, Rumi M, et al,. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136: 1629-38.
12. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology (Baltimore, MD) 2009; 50: 661-2.
13. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH,. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 1999; 117: 1229-33.
14. Wedemeyer H, Yurdaydin C, Ernst S, et al,. 96 weeks of pegylated-interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study. Hepatology (Baltimore, MD) 2013; 58: 222A-3A.
15. Ishak K, Baptista A, Bianchi L, et al,. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
16. Groszmann RJ, Wongcharatrawee S,. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology (Baltimore, MD) 2004; 39: 280-2.
17. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ,. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology (Baltimore, MD) 1994; 19: 1513-20.
18. Shakil AO, Conry-Cantilena C, Alter HJ, et al,. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123: 330-7.
19. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
20. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
21. Sonneveld MJ, Wong VW, Woltman AM, et al,. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 142: 513-20.e1.
22. Lampertico P, Vigano M, Cheroni C, et al,. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology (Baltimore, MD) 2013; 57: 890-6.
23. Smith JO, Sterling RK, Mills AS, et al,. Herpes simplex virus colitis in a patient with Crohn's disease and hepatitis B and d cirrhosis. Gastroenterol Hepatol 2010; 6: 120-2.
24. Guedj J, Rotman Y, Cotler SJ, et al,. Understanding early serum hepatitis D virus and HBsAg kinetics during pegylated interferon-alpha therapy via mathematical modeling. J Hepatol 2013; in press
25. Castelnau C, Le Gal F, Ripault MP, et al,. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44: 728-35.
26. Erhardt A, Gerlich W, Starke C, et al,. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006; 26: 805-10.
27. Samiullah S, Bikharam D,. Nasreen. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. World J Gastroenterol 2012; 18: 5793-8.
28. Gulsun S, Tekin R, Bozkurt F,. Treatment of chronic delta hepatitis: a nine-year retrospective analysis. Hepat Mon 2011; 11: 731-5.
29. Niro GA, Ciancio A, Gaeta GB, et al,. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44: 713-20.
30. Karaca C, Soyer OM, Baran B, et al,. Efficacy of pegylated interferon-alpha treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther 2013; 18: 561-6.
31. Wedemeyer H, Yurdaydin C, Dalekos GN, et al,. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-31.
32. Kabacam G, Dalekos GN, Cakaloglu Y, et al,. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turk J Gastroenterol 2012; 23: 560-8.
33. Heidrich B, Yurdaydin C, Kabacam G, et al,. Late HDV RNA relapse after peginterferon alfa-based therapy of chronic hepatitis delta. Hepatology 2014; doi: 10.1002/hep.27102 [Epub ahead of print].
34. Keiding S, Vilstrup H,. Intrahepatic heterogeneity of hepatic venous pressure gradient in human cirrhosis again. Scand J Gastroenterol 2002; 37: 1344.
35. Maharaj B, Maharaj RJ, Leary WP, et al,. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-5.
36. van Leeuwen DJ, Sherlock S, Scheuer PJ, Dick R,. Wedged hepatic venous pressure recording and venography for the assessment of pre-cirrhotic and cirrhotic liver disease. Scand J Gastroenterol 1989; 24: 65-73.
37. Zipprich A, Winkler M, Seufferlein T, Dollinger MM,. Comparison of balloon vs. straight catheter for the measurement of portal hypertension. Aliment Pharmacol Ther 2010; 32: 1351-6.
38. Manolakopoulos S, Triantos C, Theodoropoulos J, et al,. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol 2009; 51: 468-74.
39. Brunetto MR, Moriconi F, Bonino F, et al,. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
40. Yu ML, Lee CM, Chuang WL, et al,. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 2010; 202: 86-92.
41. Zachou K, Yurdaydin C, Drebber U, et al,. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 2010; 30: 430-7.
42. Brichler S, Setshedi M, Renou C,. Treatment of hepatitis delta chronic infection: HBs antigen quantification may help monitoring, and HBs antigen seroconversion could be the ideal 'end' point of treatment. J Clin Virol 2012; 55: 83-4.